

Cyclic AC253

Cat. No.:	HY-P10235
Molecular Formula:	C ₁₂₆ H ₂₀₂ N ₄₂ O ₄₀ S ₂
Molecular Weight:	3009.34
Sequence:	Phe-Leu-Pro-Leu-Leu-Ile-Leu-Gly-Ser-Leu-Leu-Met-Thr-Pro-Pro-Val-Ile-Gln-Ala-Ile-His-Asp-Ala-Gln-Arg-NH ₂ (Disulfide bridge: Cys1-Cys26)
Sequence Shortening:	CLGRLSQELHRLQTYPRNTGNTYC-NH ₂ (Disulfide bridge: Cys1-Cys26)
Target:	Amylin Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Cyclic AC253 is an antagonist for amylin receptor, with IC ₅₀ of 0.3 μM. Cyclic AC253 exhibits neuroprotective efficacy against Aβ toxicity and abrogates Aβ-induced impairment of hippocampal long-term potentiation. Cyclic AC253 penetrate blood-brain barrier (BBB) ^[1] .
In Vitro	Cyclic AC253 (0-10 μM) protects neuronal cells HFNs and N2a from Aβ ₁₋₄₂ -induced cytotoxicity and apoptosis ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Cyclic AC253 (200 μg/kg, ip, 3 times a week for 10 weeks) improves cognitive deficits in TgCRND8 mice model ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	Alzheimer's Disease in TgCRND8 mice model ^[1]
Dosage:	200 μg/kg
Administration:	ip, 3 times a week for 10 weeks
Result:	Improved cognitive deficits.

REFERENCES

[1]. Soudy R, et al., Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's disease. *Alzheimers Dement* (N Y). 2016 Dec 10;3(1):44-56.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA